乳癌ゲノム医療

DOI HANDLE Web Site オープンアクセス
  • 久保 真
    九州大学大学院医学研究院臨床・腫瘍外科
  • 甲斐 昌也
    九州大学大学院医学研究院臨床・腫瘍外科
  • 森 瞳美
    九州大学大学院医学研究院臨床・腫瘍外科
  • 倉田 加奈子
    九州大学大学院医学研究院臨床・腫瘍外科
  • 山田 舞
    九州大学大学院医学研究院臨床・腫瘍外科
  • Viva Velasquez
    九州大学大学院医学研究院臨床・腫瘍外科
  • 中村 雅史
    九州大学大学院医学研究院臨床・腫瘍外科

書誌事項

タイトル別名
  • Genome-based Medicine for Patients with Breast Cancer
  • ニュウガン ゲノム イリョウ

この論文をさがす

抄録

During the 21st century, we have witnessed the advancement in technological innovations and significant reduction in the cost of microarrays, which comprehensively analyze gene expression in cancer cells. The field of breast cancer treatment was the first to reap the benefit of this development. The practice of breast cancer has evolved tremendously since the establishment of the era of gene expression profiling. In line with this, “Precision Medicine Initiative” was launched in the United States last January 20, 2015, during President Obamaʼs State of the Union address. This program shifted the direction of treatment from the ”one-size-fits-all-approach” to individualized precise medicine. Even in Japan, the era of tailoring therapies in a patient has started. Patients and tumors are assessed and analyzed individually from a molecular and genetic standpoint in order to select and provide the best and optimal treatment strategy based on the gathered information. In this article, we summarize the genetic multi-panel tests developed so far (Prosigna®, EndoPredict®, Oncotype DX®, MammaPrint®, Curebest 95 GC Breast®, etc.) and substantiate its present and prospective clinical applications in breast cancer.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ